WHO WE ARE
Oncotelligent is a worldwide initiative and support system for cancer care.
Oncotelligent helps cancer patients at every step to prevent, treat and heal their cancer.
If a person is diagnosed with a cancer, it just devastates everything. It raises a lot of question and creates whirlwind of emotions, concerns, and questions. OncoTelligent aims to support cancer patients and family members through those early, emotional times and helps re-shape their treatment, attitude and life moving forward.
Oncotelligent, a 501 (c)(3) tax exempt non-profit organization, stands as cancer patient’s voice and works toward bringing the right information, cancer services and providers at one platform, giving people more power to choose what suits best to their condition. Oncotelligent understands that cancer can not be addressed without understanding the whole oncology practice/community and, by bringing them together-Oncotelligent will not only facilitate this collaboration, break scientific and clinical silos but also share scientific facts and information which will eventually benefit cancer patients and therefore the community.
It was 2015, while helping a family of cancer patient Dr. Pravin J. Mishra realized that there are thousands of people who are seeking similar resources/guidance and in need of help. After seeing several cases and realizing unfortunate deaths in US and India due to lack of information has challenged Dr. Mishra to start a non-profit which will become a cancer support system for everyone and especially for people who are in need of cancer care and related resources.
To help and bring resources to people who have succumbed to this vicious disease, in 2016, Dr. Mishra founded non-profit organization oncotelligent. Very soon Oncotelligent has started providing personalized cancer report to guide a therapy. By the end of the year Oncotelligent had screened more than 3000 people and saved multiple lives.
Providing cancer education, cancer screening and best available resources to prevent, treat and heal cancer.